Table 2 Adverse events across treatment cohorts
Variable | DC vaccine + placebo (n = 5) | DC vaccine + poly-ICLC (n = 9) | DC vaccine + resiquimod (n = 9) | Total (n = 23) |
|---|---|---|---|---|
Any | 1 (20%) | 9 (100%) | 8 (89%) | 18 (78%) |
Rash | 0 | 1 (11%) | 8 (89%) | 9 (39%) |
Fever | 0 | 5 (56%) | 3 (33%) | 8 (35%) |
Fatigue | 1 (20%) | 2 (22%) | 3 (33%) | 6 (26%) |
Flu-like symptoms | 0 | 2 (22%) | 0 | 2 (9%) |
Nasal congestion | 0 | 1 (11%) | 0 | 1 (4%) |
Nervous system | 0 | 4 (44%) | 2 (22%) | 4 (17%) |
Headache | 0 | 3 (33%) | 1 (11%) | 4 (17%) |
Seizure | 0 | 0 | 1 (11%) | 1 (4%) |
Sensory paresthesias | 0 | 1 (11%) | 0 | 1 (4%) |
Cognitive disturbances | 0 | 1 (11%) | 0 | 1 (4%) |
Ear pain | 0 | 1 (11%) | 0 | 1 (4%) |
Musculoskeletal | 0 | 3 (33%) | 2 (22%) | 5 (22%) |
Neck pain | 0 | 0 | 1 (11%) | 1 (4%) |
Body aches | 0 | 1 (11%) | 0 | 1 (4%) |
Myalgia | 0 | 2 (22%) | 1 (11%) | 3 (13%) |
Gastrointestinal | 0 | 1 (11%) | 1 (11%) | 2 (9%) |
Nausea | 0 | 1 (11%) | 1 (11%) | 2 (9%) |
Vomiting | 0 | 0 | 1 (11%) | 1 (4%) |
Cardiovascular / blood | 0 | 0 | 2 (22%) | 2 (9%) |
Presyncope | 0 | 0 | 1 (11%) | 1 (4%) |
Neutropenia | 0 | 0 | 1 (11%) | 1 (4%) |
